Loading...
NPI 1033167846 · Shiloh, IL · Medical Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
John Visconti is a medical oncology physician provider located in Shiloh, Illinois. This profile covers 62 Medicare and 9 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | John Visconti |
| Address | 1418 Cross St |
| City | Shiloh |
| State | IL |
| ZIP | 62269 |
| Taxonomy | Medical Oncology Physician |
| NPI Enumerated | May 4, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.8M |
| Medicaid | $149.1K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
62 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 24,400 | $40 | $1M |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 13,680 | $40 | $519.8K |
| J0897 | Injection, denosumab, 1 mg | 15,720 | $20 | $283K |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 6,190 | $40 | $235.2K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 1,240 | $80 | $100.1K |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 3,890 | $20 | $89.4K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,210 | $70 | $82.5K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 850 | $100 | $82.3K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,970 | $20 | $68.3K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 27,650 | $1 | $55.3K |
Showing 1–10 of 62
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 62 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
62 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 16 | 110 | 11,600 | $40 | $564.2K |
| J9144 | 6 | 50 | 7,740 | $40 | $341.8K |
| J1561 | 1 | 10 | 4,190 | $40 | $159.3K |
| J0897 | 21 | 410 | 2,520 | $20 | $90.8K |
| Q5119 | 8 | 40 | 1,970 | $20 | $50.6K |
| J0881 | 11 | 70 | 11,600 | $1 | $38.2K |
| Q5107 | 1 | 20 | 1,350 | $20 | $36.3K |
| J2506 | 1 | 70 | 320 | $80 | $32.9K |
| J1439 | 29 | 80 | 25,500 | $1 | $30K |
| J9217 | 117 | 160 | 140 | $130 | $21.1K |
Showing 1–10 of 62
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
9 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 1,380 | $60 | $80K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 2,180 | $20 | $32.6K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 700 | $20 | $11.2K |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 570 | $20 | $10.3K |
| 96417 | In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy… | 190 | $40 | $7.3K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 280 | $10 | $2.5K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 90 | $30 | $2.2K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 340 | $10 | $2.1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 710 | $1 | $710 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
9 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 26 | 150 | 170 | $50 | $39.9K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,876 | 14,190 | 280 | $20 | $38.9K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 49 | 80 | 150 | $40 | $29.3K |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 16 | 40 | 280 | $30 | $17.4K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 4 | 20 | 100 | $30 | $17.4K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 19 | 80 | 120 | $20 | $17.1K |
| 96417 | In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy… | 8 | 20 | 120 | $30 | $10.6K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 275 | 900 | 120 | $10 | $3.5K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 26 | 140 | 90 | $1 | $480 |
Other providers in the same ZIP code as John Visconti, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Southern Illinois Healthcare Foundation Inc | IL | Federally Qualified Health Center (FQHC) | $0 | $7.9M |
| Ssm Cardinal Glennon Childrens Hospital | IL | Pediatrics Physician | $0 | $5.4M |
| Bassam Maalouf | IL | Hematology & Oncology Physician | $1.8M | $770.9K |
| Brett Herzog | IL | Medical Oncology Physician | $1.9M | $40.7K |
| Justin Floyd | IL | Medical Oncology Physician | $1.3M | $336.2K |
| Mark Walshauser | IL | Hematology & Oncology Physician | $437.5K | $395.5K |
| O'fallon Surgical Center, LLC | IL | Ambulatory Surgical Clinic/Center | $793.7K | $0 |
| Scott Roustio | IL | Emergency Medicine Physician | $83.8K | $625.5K |
| Michael Stock | IL | Ophthalmology Physician | $669.2K | $0 |
| Raghav Govindarajan | IL | Neuromuscular Medicine (Psychiatry & Neurology) Physician | $377.7K | $282.1K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.